Ignite Creation Date:
2025-12-24 @ 4:31 PM
Ignite Modification Date:
2026-01-05 @ 6:11 PM
Study NCT ID:
NCT01614366
Status:
COMPLETED
Last Update Posted:
2015-11-13
First Post:
2012-06-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}], 'ancestors': [{'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017311', 'term': 'Amlodipine'}], 'ancestors': [{'id': 'D004095', 'term': 'Dihydropyridines'}, {'id': 'D011725', 'term': 'Pyridines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 111}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-11', 'completionDateStruct': {'date': '2014-05', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-11-11', 'studyFirstSubmitDate': '2012-06-03', 'studyFirstSubmitQcDate': '2012-06-05', 'lastUpdatePostDateStruct': {'date': '2015-11-13', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-06-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': '*SBP reduction=SBP each visit- SBPvisit2', 'timeFrame': '14 weeks', 'description': 'The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction\\* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period'}], 'secondaryOutcomes': [{'measure': 'The secondary objectives of the study include: Efficacy/Safety', 'timeFrame': '14 weeks', 'description': 'Efficacy:\n\nTo compare the sitting diastolic blood pressure (mmHg) reduction\\* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc.\n\nSafety:\n\nTo evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['amlodipine', 'DMTA07', 'hypertension'], 'conditions': ['Hypertension']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.', 'detailedDescription': 'To compare the different dose of DM combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.\n\nThe purpose of this study is to compare the antihypertensive efficacy and tolerability of different dose of DM combines with amlodipine treatment, further to explore the optimized combination dose of DM.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '50 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Male or female patient aged between 50 to 75 years old (both included);\n2. Patient with mild to moderate essential hypertension at enrollment, which defined as the following:\n\n Patient must have mean sitting SBP ≥140 and \\<180 mmHg or mean sitting DBP ≥90 and \\<110 mmHg at enrollment;\n3. Patient with normal serum potassium;\n4. Patient or his/her legally acceptance representative has signed the written informed consent form.\n\nExclusion Criteria:\n\n1. Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg);\n2. Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc;\n3. Patient is under treatment with beta-blocker prior to enrollment;\n4. A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure within 3 months before signing the written informed consent form;\n5. Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus;\n6. Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated hemoglobin \\> 9% or fasting blood sugar \\> 250 mg/dL at enrollment) or under insulin treatment;\n7. Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication;\n8. Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant;\n9. Patient with clinically relevant hematological disease;\n10. Hepatic or renal dysfunction as defined by the following parameters:\n\n * ALT or AST \\> 2 times upper limit of normal,\n * Total bilirubin \\> 2 times upper limit of normal,\n * Serum creatinine \\>2.0 mg/dl;\n11. Female patient who is pregnant or lactating;\n12. Patient with substance abuse (including alcohol) history for the past two years;\n13. Known or suspected contraindications, including allergy to DMTA07 or calcium channel blockers;\n14. Patient received other investigational drug or device within 30 days before signing the written informed consent form;\n15. Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial."}, 'identificationModule': {'nctId': 'NCT01614366', 'briefTitle': 'DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension', 'organization': {'class': 'INDUSTRY', 'fullName': 'TSH Biopharm Corporation Limited'}, 'officialTitle': 'A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension', 'orgStudyIdInfo': {'id': 'TSHDM1101'}, 'secondaryIdInfos': [{'id': 'DMTA07', 'type': 'OTHER', 'domain': 'Tshbiopharm'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'AM 5 + DM 0', 'description': 'Amlodipine 5 mg + DMTA07 0mg, once daily', 'interventionNames': ['Drug: AM 5 + DM 0']}, {'type': 'EXPERIMENTAL', 'label': 'AM 5 + DM 2.5', 'description': 'Amlodipine 5 mg + DMTA07 2.5mg, once daily', 'interventionNames': ['Drug: AM 5 + DM 0', 'Drug: AM 5 + DM 2.5']}, {'type': 'EXPERIMENTAL', 'label': 'AM 5 + DM 7.5', 'description': 'Amlodipine 5 mg + DMTA07 7.5mg, once daily', 'interventionNames': ['Drug: AM 5 + DM 0', 'Drug: AM 5 + DM 2.5', 'Drug: AM 5 + DM 7.5']}, {'type': 'EXPERIMENTAL', 'label': 'AM 5 + DM 30', 'description': 'Amlodipine 5 mg + DMTA07 30mg, once daily', 'interventionNames': ['Drug: AM 5 + DM 0', 'Drug: AM 5 + DM 2.5', 'Drug: AM 5 + DM 7.5', 'Drug: AM 5 + DM 30']}], 'interventions': [{'name': 'AM 5 + DM 0', 'type': 'DRUG', 'otherNames': ['Amlodipine (AM)', 'DMTA07 (DM)'], 'description': 'Amlodipine 5 mg + DMTA07 0mg, once daily', 'armGroupLabels': ['AM 5 + DM 0', 'AM 5 + DM 2.5', 'AM 5 + DM 30', 'AM 5 + DM 7.5']}, {'name': 'AM 5 + DM 2.5', 'type': 'DRUG', 'otherNames': ['Amlodipine (AM)', 'DMTA07 (DM)'], 'description': 'Amlodipine 5 mg + DMTA07 2.5mg, once daily', 'armGroupLabels': ['AM 5 + DM 2.5', 'AM 5 + DM 30', 'AM 5 + DM 7.5']}, {'name': 'AM 5 + DM 7.5', 'type': 'DRUG', 'otherNames': ['Amlodipine (AM)', 'DMTA07 (DM)'], 'description': 'Amlodipine 5 mg + DMTA07 7.5mg, once daily', 'armGroupLabels': ['AM 5 + DM 30', 'AM 5 + DM 7.5']}, {'name': 'AM 5 + DM 30', 'type': 'DRUG', 'otherNames': ['Amlodipine (AM)', 'DMTA07 (DM)'], 'description': 'Amlodipine 5 mg + DMTA07 30mg, once daily', 'armGroupLabels': ['AM 5 + DM 30']}]}, 'contactsLocationsModule': {'locations': [{'zip': '824', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'E-DA Hospital', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40705', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Taichung Veterans General Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '100', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'National Taiwan University Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '104', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Mackay Memorial Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '112', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Cheng Hsin General Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '112', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Taipei Veterans General Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '114', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Tri-Service General Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333', 'city': 'Taoyuan', 'country': 'Taiwan', 'facility': 'Chang Gung Memorial Hospital', 'geoPoint': {'lat': 24.99368, 'lon': 121.29696}}], 'overallOfficials': [{'name': 'Jaw-Wen Chen, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'VGHTP'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'TSH Biopharm Corporation Limited', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}